Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Oncology and Therapy
|
November 14, 2023
Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
Heidi Ko, Rebecca A Previs, Kyle C Strickland, et al.
Frontiers in Oncology
|
December 12, 2024
Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1
Zachary D Wallen, Mary K Nesline, Marni Tierno, et al.
Population Health Management
|
August 29, 2020
A Simple Algorithm for Return to Workplace Employer Antibody Testing
William H Shrank, Brian Caveney, Steve Miller, et al.
Frontiers in Oncology
|
March 18, 2025
From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates
Heidi C Ko, Kyle C Strickland, Dana Jaggessarsingh, et al.
Frontiers in Genetics
|
May 19, 2025
RNA hybrid-capture next-generation sequencing has high sensitivity in identifying known and less characterized oncogenic and likely oncogenic <i>NTRK</i> fusions in a real-world standard-of-care setting
Zachary D Wallen, Marni Tierno, Erica Schnettler, et al.
Gynecologic Oncology
|
December 4, 2024
Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers
Rebecca A Previs, Kyle C Strickland, Zachary Wallen, et al.
Briefings in Bioinformatics
|
October 29, 2024
A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors
Zachary D Wallen, Mary K Nesline, Sarabjot Pabla, et al.
Oncology and Therapy
|
March 19, 2024
The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
Mary K Nesline, Vivek Subbiah, Rebecca A Previs, et al.
Frontiers in Immunology
|
July 8, 2024
Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer
Zachary D Wallen, Heidi Ko, Mary K Nesline, et al.
Molecular Diagnosis & Therapy
|
June 7, 2025
Utilization of a Multi-modal Comprehensive Genomic and Immune Profiling Testing Strategy Results in a High Rate of Test Success and Detection of Clinically Relevant Biomarkers While Optimizing Tissue Usage
Michelle F Green, Zachary D Wallen, Heidi C Ko, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Oncology and Therapy
|
November 14, 2023
Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
Heidi Ko, Rebecca A Previs, Kyle C Strickland, et al.
Frontiers in Oncology
|
December 12, 2024
Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1
Zachary D Wallen, Mary K Nesline, Marni Tierno, et al.
Population Health Management
|
August 29, 2020
A Simple Algorithm for Return to Workplace Employer Antibody Testing
William H Shrank, Brian Caveney, Steve Miller, et al.
Frontiers in Oncology
|
March 18, 2025
From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates
Heidi C Ko, Kyle C Strickland, Dana Jaggessarsingh, et al.
Frontiers in Genetics
|
May 19, 2025
RNA hybrid-capture next-generation sequencing has high sensitivity in identifying known and less characterized oncogenic and likely oncogenic <i>NTRK</i> fusions in a real-world standard-of-care setting
Zachary D Wallen, Marni Tierno, Erica Schnettler, et al.
Gynecologic Oncology
|
December 4, 2024
Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers
Rebecca A Previs, Kyle C Strickland, Zachary Wallen, et al.
Briefings in Bioinformatics
|
October 29, 2024
A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors
Zachary D Wallen, Mary K Nesline, Sarabjot Pabla, et al.
Oncology and Therapy
|
March 19, 2024
The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
Mary K Nesline, Vivek Subbiah, Rebecca A Previs, et al.
Frontiers in Immunology
|
July 8, 2024
Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer
Zachary D Wallen, Heidi Ko, Mary K Nesline, et al.
Molecular Diagnosis & Therapy
|
June 7, 2025
Utilization of a Multi-modal Comprehensive Genomic and Immune Profiling Testing Strategy Results in a High Rate of Test Success and Detection of Clinically Relevant Biomarkers While Optimizing Tissue Usage
Michelle F Green, Zachary D Wallen, Heidi C Ko, et al.
Page
of 2